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ABSTRACT 
In a policy climate where incentives to cherry pick are minimized, Managed Care 
Organizations can implement practices that safeguard medical privacy to the extent that 
data is protected &om falling into the hands of third parties who could misuse it to 
discriminate. To the extent that these practices have been codified into the regulatory 
M e w o r k  of the Health Insurance Portability and Accountability Act (HIPAA) 
CoIlSumers may be able to rest easy about their genetic data being revealed to third parties 
who may discriminate. However, there are limitations to the use of policy instruments to 
prevent the discrimination of an entire genre of clients by market driven managed care 
organizations. Policy measures, to assure that knowledge of genetic conditions and their 
fiture costs would not be used by market Qiven managed care organizations to 
implement institutional policies and products that would implicitly discriminate against a 
genre of clients with genetic conditions, present difficulties. 
- 
A. The function of confldentiality in health care: 
Medical confrdentiality practices have traditionally served to protect several values in 
health care. These include: trust in the doctor patient relationship based in the faith that 
sensitive personal information revealed to the doctot in the course of seeking health care 
will not be revealed firrther where it could be used to stigmatize the patient and 
discriminate against this person. In addition, confidentiality practices have served to 
protect patient autonomy and dignity by allowing the patient the privacy to conduct his or 
her life without pressure from others. With the rise of the practice of informed consent 
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has increasingly been sought prior to release of confidential information. Confidentiality 
practices in health care, therefore, serve the values of trust, autonomy, patient dignity, 
and protection from discrimination and stigmatization. (Kotval, Jeroo. 2005. Genetic 
privacy in the health care system. In, Sheldon Krimsky and Peter Shorett, eds., Rights 
and Liberties in the Biotech Age: why we need a genetic bill of rights. Lanham, MD: 
Rowman & Littlefield Publishers, c 2005). 
The rise of market-driven managed care as a major institution for delivering health care 
in the late twentieth and early twenty-first century raises several concerns related to 
medical confidentiality. This institution is the descendent of commercial insurers who 
have a history of cherry picking health clients through a variety of means such as risk 
rating and selective marketing. To this, managed care has added a host of strategies to 
shift costs to patients and shifting risks to providers by implementing co-payments and 
deductibles for clients and capitated payments for physicians. 
The advent of pre-symptomatic and predispositional genetic testing, with its capacity for 
providing information about the future health status of individuals, would be of interest to 
such an institution since these tests can identify future patient costs. Hence, Kotval has 
referred to market-driven managed care organization as "double agents" since they at the 
same time claim to provide quality care and save costs. (See Kotval, J.S. "Market-driven 
managed care and confidentiality of genetic tests: the institution as double agent," Albany 
Law Journal of Science and Technology, 1998, Volume 9, Nol, pages 1-25). The 
availability of this information electronically only increases the ease with which it can be 
transmitted and manipulated and hence increases the risk for harm to individuals because 
of a knowledge of their genetic make-up. 
B. Study of managed care organizations in New York State: 
We have completed a study of managed care organizations in New York State to examine 
the confidentiality practices of these institutions operating in a mature and uniform policy 
environment. Policies that reliably protect medical confidentiality must not only address 
the security of the health data, including unauthorized disclosures, they need to address 
the illegitimate internal use of such data for non-medical purposes and the institutional 
incentives to abuse confidentiality. Only then can we be assured that the umbrella of 
values upheld through traditional confidentiality practices are safeguarded. 
Major elements of the New York State policy framework governing this include: 
0 Prohibit use of health status information in determining eligibility 
for health insurance, 
0 Prohibit use of genetic test information in asymptomatic 
individuals to determine access to health insurance; i.e., a positive 
genetic test in an asymptomatic individual cannot be deemed a 
preexisting condition, 
a Guarantee renewal of individual insurance regardless of health 
status or claims experience, 
0 Require all HMOs to offer a standard set of benefits for individual 
insurance products, 
a Require individual insurance plans to be community rated. 
Further, informed consent laws provide protections to persons from use of genetic 
information without their consent. Insurance laws also restrict who can request genetic 
testing and who may use test results and for what purpose. New York State Civil Rights 
law further offers protections on the performance of genetic tests including specifying 
what constitutes informed consent. Re-disclosure of test results to other parties without 
individual consent is prohibited. 
As a result of this policy framework incentives to use member medical information for 
other than health purposes, such as structuring benefit packages, may be eliminated in 
New York State. How does this translate into privacy practices within the institutions? 
We initially contacted 20 health plans and completed an in-depth study of seven. The 
study design included obtaining information from health plans using structured interview 
question based on health privacy recommendations from national organizations. 
Interview questions sought answers to questions related to the management, security, and 
utilization of medical information. In addition we reviewed a variety of materials from 
twenty-three plans to analyze their practices related to medical confidentiality. These 
documents, such as subscriber contracts and member handbooks, were reviewed for 
content related to medical records use and procedures and notice given to members on 
protecting confidentiality. 
We especially sought to (1) discover potential gaps in protecting genetic information, (2) 
identify the limits of any regulatory policy to protect confidential genetic test 
information, and (3) identify best practices targeted to achieving both an actual and 
cultural shift in organizational practice. 
!HIGHLIGHTS OF FINDINGS REGARDING CONFIDENTIALITY PRACTICES 
OF NEW YORK STATE MCOs: 
Who has access, how much, and how is this access to information obtained? 
a All enrollment contracts have provisions for health plan 
subscribers to authorize release of medical information to health 
plan at time of enrollment. 
a Staff within the Managed Care Organization have access to 
i 
personal health information including encounter data though the 
level of access to detailed personal health information is restricted 
to personnel in a managed organization by job function. In an 
electronic system, this is done by password protections and limits 
on data fields they can access. For example, utilization review and 
disease management staffs appear to have the most access to 
individual clinical information. Most health plans have specific 
policies and procedures for internal disclosure of individually 
identifiable medical information. 
e Health plan requests for patient medical information from 
providers are limited to minimum amount needed to make decisions 
and administer benefit contract. This is subject to the needs of the 
plan if the benefit determination is contested. Patient medical 
information is therefore exposed to the health plan during the 
appeals process subject to "informed consent'' by the patient. 
e Health plans do not routinely receive or ask for results of 
diagnostic tests, including genetic tests and access to the full 
medical record fiom physician office is sought only in a very 
limited number of cases and is subject to the providers discretion. 
Situations where such access is sought would include suspicions of 
fraud, or where extensive disease management is necessary. Patient 
consent in such cases is not required. 
e Release of genetic test results by testing provider is controlled by 
legally mandated informed consent procedures where the patient is 
required to provide written informed consent for each disclosure of 
genetic information. Health plans do not have access to this 
information without specific member consent according to New 
York State law. 
Do managed care organizations have a culture of care for medical privacy? 
e Member materials on use and disclosure of personal information by 
the health plan do not address the concerns that the public seems 
to have about confidentiality of personal information. 
0 An organizational culture which values confidentiality as important 
to a relationship with members is not easily apparent in individual 
managed care organizations. 
. .  
8 Nevertheless, consumer concerns over inappropriate use of genetic 
information by managed care organizations in New York State may 
be unfounded at this time because of the current regulatory 
environment and limited use of genetic information by most 
providers and health plans. 
8 Health plan personnel receive training regarding confidentiality 
practices and procedures. However, concerns about obtaining and 
disclosing genetic information specifically is generally lacking. 
8 Some health plan policies and procedures do not explicitly address 
internal disclosure of any individually identifiable medical 
information to health plan staff for non-health purposes. Similarly, 
some health plans do not have adequate formal policies and 
procedures for release of individually identifiable information to 
employers (including self-funded plans). These policies are covered 
under the plan’s general procedures for release to third parties. 
Conclusions: 
Our findings indicate that in a policy climate where incentives to cherry pick are 
minimized institutions can implement practices that safeguard medical privacy to the 
extent that data is protected from falling into the hands of third parties who could mis-use 
it to discriminate. To the extent that these practices can be codified into a legislative or 
regulatory policy framework consumers may be able to rest easy about their genetic data 
being revealed to third parties who may discriminate. However, this knowledge is 
accessible to MCOs themselves and could be used to re-structure benefit packages, 
increase overall costs or dramatically change the way in which employers cover health 
insurance. These possibilities justify consumer concerns about use of genetic information 
to disenfranchise them from the health care system. Only guaranteed universal health care 
can assuage these concerns in the long run. 
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